Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for REGORAFENIB
- Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
- caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
- KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
- Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
- Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
- Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
- Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
- The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
- Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
- Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
- Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
- Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
- A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
- Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
- Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma
- Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
- Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
- Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
- Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
- Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients.
- Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Regorafenib in Patients With Refractory Primary Bone Tumors
- Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
- Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
- Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
- Surufatinib Monotherapy for Advanced Colorectal Cancer in Later Line
- A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
- Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105
- A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
- FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
- HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
- FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
- Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
- A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure
- Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
- A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
- Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- RegoNivo vs Standard of Care Chemotherapy in AGOC
- Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
- T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
- Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
- The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
- Regorafenib and Nivolumab Combined Versus TACE in Intermediate-Stage HCC Beyond Up-to-7 (RENOTACE)
- Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
- A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
- A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
- Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)
- Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
- A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
- Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
- Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
- An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.
- TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
- The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
- Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Intermediate-risk, Stage II-III Rectal Cancer
- Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
- Optimization for Regorafenib in HCC
- Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
- Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
- Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
- A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer
- Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
- Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
- A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
- Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
- Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
- Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
- Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
- Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
- Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
- Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
- Regorafenib and Nivolumab in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
- Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
- Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
- A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
- Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
- Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Zinc Supplement in Regorafenib Treated mCRC Patient
- A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
- Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
- Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
- Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
- Phase II Study of Regorafenib as Maintenance Therapy
- Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
- Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
- Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
- Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
- PDR001 Plus Imatinib for Metastatic or Unresectable GIST
- Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
- QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
- RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
- Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- A Study of CS1003 in Subjects With Advanced Solid Tumors
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- Regorafenib and Nivolumab Simultaneous Combination Therapy
- Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
- An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
- Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
- Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
- Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
- Epacadostat and Pembrolizumab in Patients With GIST
- Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
- Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
- Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
- Study of Regorafenib in Patients With Advanced Myeloid Malignancies
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
- Regorafenib in Relapsed Glioblastoma
- The Drug Rediscovery Protocol (DRUP Trial)
- Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
- Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
- Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
- The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
- A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
- Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
- A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
- Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
- Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
- A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
- Stivarga Real Life Evidence in Hungary
- Phase II Study of Perindopril and Regorafenib in mCRC
- Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
- Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
- Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
- Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
- REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
- Efficacy of Ginseng for Patients on Regorafenib
- Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
- Study of Regorafenib and Sildenafil for Advanced Solid Tumors
- Regorafenib in Metastatic Colorectal Cancer
- Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
- Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
- Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
- Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
- Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
- A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
- Regorafenib Phase I Study in Mainland Chinese Patients
- A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
- Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
- Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
- A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
- Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer
- Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
- Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
- Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
- Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
- Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
- A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
- Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
- Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
- Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
- Regorafenib + Panitumumab for Colorectal Cancers
- Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
- Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
- Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- Regorafenib Versus Placebo to Treat Cholangiocarcinoma
- Study of Ruxolitinib in Colorectal Cancer Patients
- Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
- Single Agent Regorafenib in Refractory Advanced Biliary Cancers
- Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
- Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Regorafenib and Cetuximab in Patients With Advanced Malignancy
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
- A Study of Regorafenib in Advanced Pancreatic Cancer Patients
- A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Safety and Effectiveness of Regorafenib
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
- Effect of Neomycin on the Pharmacokinetics of Regorafenib
- Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
- Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
- Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
- Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
- Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
- Regorafenib Post-marketing Surveillance in Japan
- Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
- FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
- Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
- Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
- Regorafenib Post-marketing Surveillance
- Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
- Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
- Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
- Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
- Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
- Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
- Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
- Effect of Rifampin on the Pharmacokinetics of BAY73-4506
- Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
- Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
- First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
- BAY73-4506 Probe Substrate Study
- Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
- Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
- Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
- Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
- Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
- Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
Clinical trials list
click for details